Navigation Links
Pharmasset Reports Fiscal Year End 2011 Financial Results
Date:11/14/2011

.1 million, or $1.07 per share for the same period in 2010.

"In 2011, we have made significant advances with our HCV nucleotide analogs," stated Schaefer Price, President and Chief Executive Officer. "At the recent AASLD meeting we reported consistently high SVR results from PSI-7977 and ribavirin dosed with or without interferon across genotypes 1, 2 and 3. This encouraging data in combination with PSI-7977's good safety profile and high barrier to resistance have enabled us to rapidly initiate the first interferon-free phase 3 program in the industry. We are excited to pursue an interferon-free regimen in phase 3 since interferon intolerability keeps most patients from being treated for their HCV. We anticipate filing for marketing approval in the US and Europe in the second half of 2013 and hope to be the first to introduce an interferon–free regimen in the marketplace."

Calendar Year 2012 Anticipated Milestones:-- Initiate Phase 3 POSITRON trial with PSI-7977 and ribavirin in patients with HCV GT2 or GT3 in the first quarter of 2012-- Report SVR24 HCV GT1 from Phase 2b PROTON study during the first quarter of 2012-- Report interim QUANTUM data in second quarter of 2012-- Report SVR12 from the 12-week treatment arm of ATOMIC during the second quarter of 2012.-- Report interferon-free ELECTRON data in subjects with HCV GT1 in the first half of 2012-- Initiate NEUTRINO, an interferon free, Phase 3 study of PSI-7977 and RBV for 12 weeks in subjects with all HCV genotypes who cannot take interferon in mid 2012.-- Report SVR12 from QUANTUM in the second half of 2012-- Report SVR12 from the arm with HCV genotype 2 or 3 subjects of Part 3 of ELECTRON during the third quarter of 2012.-- Report SVR12 from ATOMIC 24-week treatment arms during the second half of 2012.About PharmassetPharmasset is a clinical-stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections. Pharmasset's primary
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
2. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
3. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
4. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
5. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
6. Pharmasset to Present at Two Upcoming Investor Conferences
7. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
8. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
9. Pharmasset Reports Fiscal First Quarter 2009 Financial Results
10. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
11. Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... (PRWEB) April 17, 2015 CIO Review ... for its 20 Most Promising Pharma and Life Science ... MMIS’s MediSpend global compliance software platform for life sciences ... selected by a panel of experts and members of ... entrepreneurship. “MMIS’s MediSpend Platform has been on our radar ...
(Date:4/17/2015)... TX (PRWEB) April 17, 2015 ... and proteomics technologies, announced today that it is ... system, an innovative multiplex PCR based targeted sequencing ... resolution sequence analysis, that enables accurate detection of ... Relay-PCR™ and Omega-Primer™ technologies. The company will collaborate ...
(Date:4/16/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... on Thursday, April 30, 2015 at 4:00 PM Eastern ... a conference call at 4:30 PM Eastern Time to ... for the future. , The conference call will be ... and in the Investor Relations section of Cytokinetics’ website ...
(Date:4/16/2015)... Streetsboro, Ohio (PRWEB) April 16, 2015 ... Safety Index, overexertion involving an outside source was ... injuries. This includes injuries related to lifting, pushing, ... $15.1 billion in direct costs. The David Round ... Round is committed to working hard to develop ...
Breaking Biology Technology:MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2
... About 15 years ago, MIT professors Robert Langer ... programmable, wirelessly controlled microchip that would deliver drugs after ... researchers and scientists from MicroCHIPS Inc. reported that they ... doses of an osteoporosis drug normally given by injection. ...
... Researchers at the Wyss Institute for Biologically Inspired Engineering ... from DNA that could potentially seek out specific cell ... deliver important molecular instructions, such as telling cancer cells ... own immune system, the technology might one day be ...
... ORLANDO, Fla., Feb. 16, 2012   GeneLink ... biotech company, has completed the sale of the ... Life Sciences, Inc. (GeneWize)  to Capsalus Corp. (OTCBB: ... and wellness marketplace.  As previously disclosed, GeneLink and ...
Cached Biology Technology:Successful human tests for first wirelessly controlled drug-delivery chip 2Successful human tests for first wirelessly controlled drug-delivery chip 3Harvard's Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses 2Harvard's Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses 3GeneLink Biosciences Completes Sale of GeneWize Life Sciences 2
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... Calif., June 6, 2012  Amarantus BioSciences, Inc. (OTCBB: ... products for the treatment of Parkinson,s disease and ... today announced that it has been selected to ... Conference in New York City at Le Park ...
... A rose by any other name would smell as ... the chemical components of its fragrance or discovering where its ... biology, an organism,s scientific (taxonomic) name is the key to ... genetic, ecological, and agricultural particulars of every known plant -- ...
... /PRNewswire-iReach/ -- As a driving force behind today,s ... look for ways to expand its employee time ... efforts, uAttend is pleased to announce that TimeClockDeals.com is ... software services. TimeClockDeals.com is a leading retailer ...
Cached Biology News:Amarantus BioSciences to Present at the National Investment Banking Association's (NIBA)122nd Conference in New York City 2Amarantus BioSciences to Present at the National Investment Banking Association's (NIBA)122nd Conference in New York City 3New release of Web-based resource resolves confusion over plant names 2New release of Web-based resource resolves confusion over plant names 3uAttend Time Tracking Solutions Available at TimeClockDeals.com 2
GOAT ANTI HUMAN PSA (ISOFORM 1)...
... Immunogen: Synthetic peptide derived from the N-terminal ... ZO-1. Specificity: Specific for the N-terminus ... Reactivity: Human Dog Rat Mouse (positive controls: ... mouse liver heart blood vessel and brain ...
p-Raf-1 (Ser 338/Tyr 341)-R...
Human/Mouse APLP-1 MAb (Clone 354020) ENTREZ GeneID: 333...
Biology Products: